MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.810
+0.070 (4.02%)
Sep 11, 2026, 4:00 PM EDT - Market closed
MediciNova Revenue
MediciNova had revenue of $458.44K in the quarter ending June 30, 2026, with 240.60% growth. This brings the company's revenue in the last twelve months to $920.48K. In the year 2025, MediciNova had annual revenue of $409.66K.
Revenue (ttm)
$920.48K
Revenue Growth
+583.87%
P/S Ratio
96.79
Revenue / Employee
$153,414
Employees
6
Market Cap
89.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 409.66K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 4.04M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 6.00M | 5.20M | 647.99% |
| Dec 31, 2012 | 802.58K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 263.88K | -540.19K | -67.18% |
| Dec 31, 2005 | 804.07K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 68.47M |
| ImmuCell | 30.68M |
| Verrica Pharmaceuticals | 30.32M |
| Atara Biotherapeutics | 6.19M |
| Nutriband | 1.62M |
| Rallybio | 646.00K |
| Cardiff Oncology | 508.00K |
| NeOnc Technologies Holdings | 39.99K |
MNOV News
- 1 day ago - MediciNova Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 days ago - MediciNova to Participate in Two Investor Conferences in September - GlobeNewsWire
- 4 weeks ago - MediciNova Quarterly report: Q2 2026 - Filings
- 1 month ago - MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients - GlobeNewsWire
- 2 months ago - MediciNova CEO Provides Shareholder Update - GlobeNewsWire
- 3 months ago - MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment - GlobeNewsWire
- 3 months ago - MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewsWire
- 3 months ago - MediciNova Slides: Corporate presentation - Filings